GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Accounts Payable

Cybin (CYBN) Accounts Payable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Accounts Payable?

Cybin's Accounts Payable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Cybin's annual Accounts Payable increased from Mar. 2021 ($2.22 Mil) to Mar. 2022 ($4.16 Mil) but then declined from Mar. 2022 ($4.16 Mil) to Mar. 2023 ($4.14 Mil).


Cybin Accounts Payable Historical Data

The historical data trend for Cybin's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Accounts Payable Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Accounts Payable
- 2.22 4.16 4.14

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.22 4.14 - - -

Cybin Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Cybin Accounts Payable Related Terms

Thank you for viewing the detailed overview of Cybin's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Cybin (CYBN) Business Description

Traded in Other Exchanges
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.